<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Altretamine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00488</strong>&#160; (APRD00652)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00488/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00488/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00488.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00488.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00488.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00488.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00488.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00488">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Altretamin</td><td>German</td><td>INN</td></tr><tr><td>Altretamina</td><td>Italian/Spanish</td><td>INN/DCIT</td></tr><tr><td>Altr&#233;tamine</td><td>French</td><td>INN/DCF</td></tr><tr><td>Altretaminum</td><td>Latin</td><td>INN</td></tr><tr><td>Hexamethylmelamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>WHO</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Hexalen</td><td>Eisai</td></tr><tr><td>Hexastat</td><td>ProStrakan</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents-alkylating">Antineoplastic Agents, Alkylating</a></li></ul></td></tr><tr><th>CAS number</th><td>645-05-6</td></tr><tr><th>Weight</th><td>Average: 210.2794<br>Monoisotopic: 210.159294606</td></tr><tr><th>Chemical Formula</th><td>C<sub>9</sub>H<sub>18</sub>N<sub>6</sub></td></tr><tr><th>InChI Key</th><td>UUVWYPNAQBNQJQ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00488.gif?1265922772">show</a>(9.6 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Triazines</td></tr><tr><th>Subclass</th><td>Aminotriazines</td></tr><tr><th>Direct parent</th><td>Aminotriazines</td></tr><tr><th>Alternative parents</th><td>Tertiary Amines; Polyamines</td></tr><tr><th>Substituents</th><td>tertiary amine; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.</td></tr><tr><th>Pharmacodynamics</th><td>Altretamine is a novel antineoplastic agent. The precise mechanism by which altretamine exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, altretamine resembles the alkylating agent triethylenemelamine, yet <i>in vitro</i> tests for alkylating activity of altretamine and its metabolitics have been negative. Altretamine has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement of cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, <i>in vitro</i> and <i>in vivo</i>, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown.</td></tr><tr><th>Mechanism of action</th><td>The precise mechanism by which altretamine exerts its cytotoxic effect is unknown although it is classified as an alkylating anti-neoplastic agent. Through this mechanism, the drug is metabolized into alkylating agents by N-demethylation. These alkylating species consequently damage tumor cells.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>94%</td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>Human urinary metabolites were Ndemethylated homologues of altretamine with </td></tr><tr><th>Half life</th><td>4.7-10.2 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9817</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8794</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7168</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7414</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9531</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9797</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7702</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8369</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7122</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5779</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8821</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8293</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8823
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9793
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7475 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8907
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8735
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Eisai inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.aaipharma.com">AAIPharma Inc.</a></li>
<li><a href="http://www.eisai.com">Eisai Inc.</a></li>
<li><a href="http://www.excella-pharma-source.de">Excella GmbH</a></li>
<li>MGI Pharma</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Risk of hypotension</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>